Treatment Access Solution
A collaboration with Pfizer
The Max Foundation is partnering with Pfizer on a pilot program for international product access for Xalkori® (crizotinib) to help ensure that international prescription assistance requests are addressed consistently and objectively. The collaboration is designed to help patients outside of the U.S. living in lower-income economies, specifically uninsured and underinsured persons living where product is either not available commercially or significant access hurdles exist and where local market initiatives cannot address the request.
Requests for Xalkori® (crizotinib) must meet specified criteria. View our global map and click on individual countries to learn where this collaboration is operating today. Contact us for more information about access to Xalkori® (crizotinib) in these countries.